The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

UnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...

The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The research also highlighted that predominant indicators for Gleevec nonadherence were cognitive functioning, whether to perform therapeutic drug monitoring (if_TDM), global health status score, ...